The Gilead Génese program distinguishes several research projects in areas of oncology, such as breast cancer, and virology such as chronic viral hepatitis, HIV/AIDS and Covid-19, and the trophy delivery ceremony took place yesterday, November 8, at Champalimaud Foundation.

Inês Bártolo, a researcher at the Medicine Research Institute of the Faculty of Pharmacy of the University of Lisbon (iMed.Ulisboa), saw her work on spiro-β-lactam compounds, broad-spectrum antivirals, with the potential to fight various pathogens such as the parasite of malaria, HIV and influenza viruses. The development of broad-based antiviral drugs may enable the emergence of diseases resistant by increasing and re-emerging threats and spectra by viruses and antiviral agents with RNA treatments.

This project develop and characterize a new integrated-β-specific against the main complementary RNA viruses (influenza virus, complementary syncytial virus and SARS-CoV-activity-2) in different systems, including mice, and their mechanism of action. The aim is to develop the first spiro-β-lactam antiviral agent for target RNA viruses.